Global law firm Dentons has advised digital health company Kaia Health Software GmbH on its Series C financing, in which the company is raising US$75 million to expand its clinical capabilities and transform the treatment pathway for musculoskeletal (MSK) and chronic obstructive pulmonary disease (COPD) in the US and Europe.
The funding round was led by a leading growth fund with support from existing investors, including Optum Ventures, 3VC, Balderton Capital, Heartcore Capital, Symphony Ventures and A Round Capital.
Kaia is the global leader in digital therapies with more than 400,000 users. The company markets an individualized digital platform for clinically proven therapies to help people with chronic pain receive effective treatment without the physical presence of a doctor or physiotherapist. Using computer vision technology, the user receives individualized suggestions for improvement in the performance of therapy exercises.
Kaia intends to use the fresh capital to further develop its digital therapy solutions and to collaborate with experts from various medical disciplines to develop new solutions for additional medical conditions. In the wake of the COVID-19 pandemic, the company continues to see increased demand for its digital platform.
Konstantin Mehl, co-founder & CEO Kaia Health Software Inc, said: “As in previous years, the cooperation with Dentons has been excellent. We appreciate the trusting cooperation and the great determination of Mr. Strassner and his team.”
“Mr. Strassner and his team represented us with the utmost professionalism and dedication in all aspects of our US$75 million Series C financing round and facilitated a smooth closing with legacy and new investors and their law firms,” added Manuel Thurner, co-founder & Managing Director Kaia Health Software GmbH.
This is the second time that partner Thomas Strassner and the Dentons team have advised Kaia on all aspects. Strassner and his team regularly advise on both the investor and corporate side of venture capital transactions, particularly in the life sciences and technology sectors.
